Expression of CD80 and CD86 costimulatory molecules are potential markers for better survival in nasopharyngeal carcinoma

被引:17
作者
Chang, Cheng-Shyong [1 ]
Chang, Julia H.
Hsu, Nicholas C.
Lin, Hsuan-Yu
Chung, Chih-Yuan
机构
[1] Changhua Christian Hosp, Dept Internal Med, Div Hematol Oncol, Changhua, Taiwan
[2] Changhua Christian Hosp, Dept Pathol, Changhua, Taiwan
[3] Changhua Christian Hosp, Dept Med Educ & Res, Changhua, Taiwan
关键词
D O I
10.1186/1471-2407-7-88
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: B7 Costimulatory signal is essential to trigger T-cell activation upon the recognition of tumor antigens. This study examined the expression of B7-1 (CD80) and B7-2 (CD86) costimulatory molecules along with HLA-DR and the presence of infiltrating lymphocytes and dendritic cells to assess their significance in patients with nasopharyngeal carcinoma (NPC). Methods: Expression of CD80, CD86, HLA-DR, S-100 protein and the presence of infiltrating lymphocytes and follicular dendritic reticulum cells were immunohistochemically examined on the paraffin-embedded tissue blocks from newly diagnosed NPC patients (n = 50). The results were correlated with clinical outcome of patients. Results: CD80 and CD86 were each expressed in 10 of 50 cases in which they co-expressed in 9 cases. Univariate analysis revealed that patients with CD80/CD86 expression had significantly better overall survival than those without it ( P = 0.017), but after adjustment for stage, nodal status, and treatment, the expression of CD80/CD86 did not significantly correlate with overall survival. Expression of HLA-DR and the presence of infiltrating lymphocytes and dendritic cells did not appear to have impact on the survival of patients. Conclusion: Expression of CD80 and CD86 costimulatory molecules appears to be a marker of better survival in patient with NPC.
引用
收藏
页数:7
相关论文
共 14 条
[1]  
AGATHANGGELOU A, 1995, AM J PATHOL, V147, P1152
[2]   Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized intergroup study 0099 [J].
Al-Sarraf, M ;
LeBlanc, M ;
Giri, PGS ;
Fu, KK ;
Cooper, J ;
Vuong, T ;
Forastiere, AA ;
Adams, G ;
Sakr, WA ;
Schuller, DE ;
Ensley, JF .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (04) :1310-1317
[3]   B70 ANTIGEN IS A 2ND LIGAND FOR CTLA-4 AND CD28 [J].
AZUMA, M ;
ITO, D ;
YAGITA, H ;
OKUMURA, K ;
PHILLIPS, JH ;
LANIER, LL ;
SOMOZA, C .
NATURE, 1993, 366 (6450) :76-79
[4]  
Fleming ID, 1997, AJCC CANC STAGING MA, P31
[5]  
FREEMAN GJ, 1989, J IMMUNOL, V143, P2714
[6]   CLONING OF B7-2 - A CTLA-4 COUNTER-RECEPTOR THAT COSTIMULATES HUMAN T-CELL PROLIFERATION [J].
FREEMAN, GJ ;
GRIBBEN, JG ;
BOUSSIOTIS, VA ;
NG, JW ;
RESTIVO, VA ;
LOMBARD, LA ;
GRAY, GS ;
NADLER, LM .
SCIENCE, 1993, 262 (5135) :909-911
[7]   CD28-MEDIATED SIGNALING CO-STIMULATES MURINE T-CELLS AND PREVENTS INDUCTION OF ANERGY IN T-CELL CLONES [J].
HARDING, FA ;
MCARTHUR, JG ;
GROSS, JA ;
RAULET, DH ;
ALLISON, JP .
NATURE, 1992, 356 (6370) :607-609
[8]   CD28/B7 system of T cell costimulation [J].
Lenschow, DJ ;
Walunas, TL ;
Bluestone, JA .
ANNUAL REVIEW OF IMMUNOLOGY, 1996, 14 :233-258
[9]   Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma [J].
Lin, JC ;
Wang, WY ;
Chen, KY ;
Wei, YH ;
Liang, WM ;
Jan, JS ;
Jiang, RS .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (24) :2461-2470
[10]   Outpatient weekly 24-hour infusional adjuvant chemotherapy of cisplatin, 5-fluorouracil, and leucovorin for high-risk nasopharyngeal carcinoma [J].
Lin, JC ;
Jan, JS ;
Chen, KY ;
Hsu, CY ;
Liang, WM ;
Wang, WY .
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2003, 25 (06) :438-447